

PATENT
Docket No. 3816-4000
Facsimile

32 has been amended to identify the SEQ ID NOs for the sequences recited therein. Support for the amendment is found in originally filed claim 32 and in the drawings, Figs. 6, 7, 8 and 9. The amendment does not affect the scope of the invention claimed and should not limit the scope of the invention. No new matter has been added, and entry is respectfully requested.

RESPONSE

The Examiner has required compliance with the rules for sequence identification under 37 C.F.R. § 1.821-1.825. Specifically, it was pointed out that the SEQ ID NOs. for the peptides listed in claim 32 must be provided. Claim 32 has been so amended. It is believed that the application now complies with 37 C.F.R. § 1.821-1.825 and that examination can proceed.

The Office Action and the present response was discussed with the Examiner. The courtesy extended is deeply appreciated.

Respectfully submitted,

Dated: November 27, 2001



Maria C. H. Lin
Registration No. 29,323

MORGAN & FINNEGAN, L.L.P.
345 Park Avenue
New York, New York 10154
(212) 758-4800
(212) 751-6849
Direct line: (212) 415-8745

PATENT
Docket No. 3816-4000
Facsimile

APPENDIX I

Claims

9. (Thrice Amended). The method according to claim 8, wherein said VH-chain is nucleotides 1 to 381 of [Seq.] SEQ ID NO: 143 and said VL chain is nucleotides 1 to 321 of [Seq.] SEQ ID No.: 141.
10. The method according to claim 9 wherein said selection step [involves] comprise:
a first step:
- (i) binding of [the] display vehicles expressing an anti-human antigen receptor selected from the group consisting of:
 - (a) [on] an immobilized target antigen or a fragment[s] thereof;
 - (b) [on optionally labeled] cells expressing the target human antigen or a fragment[s] thereof, wherein the cells are optionally labelled;
 - (c) [or to] a soluble[, preferably labeled] human target antigen or a fragment[s] thereof, the human target antigen being optionally labelled;
 - (ii) removing by washing off [non-specifically binding] the display vehicles that are not bound to [(a and b)] (a) or (b) and subsequently elut[ion]ing [of specifically binding] the display vehicles that are bound to (a) or (b), [or] and
 - (iii) [positive enrichment of] positively enriching the target human antigen - bound display vehicles [(b and c) from target antigen solution or] from the suspension[s] of cells expressing the target human antigen (b) or from the target human antigen (c);
- [thus] the said isolated display vehicles [including their] comprising the desired anti-human antigen receptor[s] bound to the target human antigen being optionally [being] multiplied by replication and subjected to further rounds of in vitro selection [as described in] steps (i) to (iii).

PATENT
Docket No. 3816-4000
Facsimile

11. The method according to claim 10 wherein prior to said selection step either said VH or said VL chain is selected for binding to said ~~target human~~ antigen together with a surrogate V chain.
13. The method according to claim 12 wherein said selection of a suitable combination involves
- (a) testing [one and] the same VH chain in combination with a variety of different VL chains for binding to said ~~target~~ human antigen; or
 - (b) testing [one and] the same VL chain in combination with a variety of different VH chains for binding to said ~~target~~ human antigen.
18. An anti-human antigen receptor obtained by the method according to claim 1, said anti-human antigen receptor being low or not immunogenic in humans, and comprising a combination of functionally rearranged VH and VL chains wherein at least said VH chain is derived [preferably] from essentially unprimed mature human B-lymphocytes and said VL chain is derived from a naturally occurring human B cell repertoire.
22. The anti-human antigen receptor according to claim 18 wherein said VH is nucleotides 1 to 381 of [Seq.] SEQ ID NO: 143 and said VL chain is nucleotides 1 to 321 of [Seq.] SEQ ID No.: 141.
28. An anti-human antigen receptor obtained by the method according to claim 17, said [anti-]~~target~~ human antigen being characterized in that it is derived from human sequences, and is specific for the native human 17-1A antigen.
31. The anti-human antigen receptor of claim 29 recognizing an epitope of the extracellular domain of the 17-1A antigen preferably comprising at least one amino acid sequence, [of peptide Nos. 8, 11, 13, 14, 59, 60, 77 and 79] SEQ ID NOs: 29, 32, 34, 35, 80, 81, 98, 100.
32. The anti-human antigen receptor of claim 31, wherein the VH chain comprises at least one CDR of one of the following two sequences [shown in Fig. 7 (nucleotides 1 to 381 of SEQ ID NO: 143)] and [Fig. 8 (nucleotides 1 to 339 of SEQ ID NO: 145)] and [or] the VL chain comprises at least one CDR of

PATENT
Docket No. 3816-4000
Facsimile

the following two sequences [shown in Fig. 6 ([nucleotides 1 to 321 of SEQ ID NO: 141])] and [Fig. 9 ([nucleotides 1 to 321 of SEQ ID NO: 147])].